Fine Foods & Pharmaceuticals N T M S p A : H1-2021 Results Presentation

H1-2021Results

Presentation

16/09/21

	HALF YEAR 2021	2
	RESULTS PRESENTATION

Disclaimer

This document has been prepared by Fine Foods & Pharmaceuticals N.T.M. S.p.A. for the sole purpose described herein. The information herein is provided on a strictly confidential basis. By receiving this document the recipient undertakes with the Company to maintain the contents of the document and the document itself strictly confidential. This document may not be copied, distributed or reproduced in whole or in part, nor passed to any third party without the written consent of the Company.

The information contained herein does not purport to be comprehensive. The content of this document has a merely informative nature and is not to be construed as providing investment advice. Interested parties should conduct their own investigation and analysis of the Company and the data set forth in this document.

The statements contained herein have not been independently verified. No representation or warranty, either express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reliability of the information contained herein. Neither the Company nor any of its representatives shall accept any liability whatsoever (whether in negligence or otherwise) arising in any way in relation to such information or in relation to any loss arising from its use or otherwise arising in connection with this presentation.

The information contained in this document, unless otherwise specified is only current as of the date of this document. Unless otherwise stated in this document, the information contained herein is based on management information and estimates. This presentation includes certain forward looking statements, projections, objectives and estimates reflecting the current views of the management of the Company with respect to future events. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward- looking statements as a prediction of actual results. All forward-looking statements included herein are based on information available to the Company as of the date hereof. The Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by applicable law. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise

FINE FOODS	HALF YEAR 2021	3
	RESULTS PRESENTATION

Fine Foods

We create value

FINE FOODS	HALF YEAR 2021	4
	RESULTS PRESENTATION

Consolidated

Financial

Highlights

figures reported in this presentation have been prepared in accordance with

IAS/IFRS

	H1-2021	H1-2020
REVENUES	€ 98.6 mln	€ 75.4 mln	+ 31%
EBITDA*	€	13.1 mln	€ 8.9 mln	+ 47%
EBITDA MARGIN *	13.3%	11.9%
EBIT*	€	6.7 mln	€ 3.3 mln	+ 102%

H1-2021	H1-2020
REVENUES OF FINE FOODS € 92.6 mln	€ 75.4 mln	+ 23%
STAND ALONE

➝		* EBITDA AND EBIT ADJUSTED FOR NON RECURRING COSTS AMOUNTING TO 1.2 €M IN 2020 AND 2.8 €M IN 2019

FINE FOODS	HALF YEAR 2021	5
	RESULTS PRESENTATION

Fine Foods I.D.

Fine Foods & Pharmaceuticals N.T.M. S.p.A., listed on the STAR segment of the MTA of Borsa Italiana, is an independent Italian Contract Development & Manufacturing Organisation (CDMO). It develops and manufactures finished products for the pharmaceutical and nutraceutical industry

The Fine Foods Group is also active in the cosmetic, biocide and medical device industries with the recent acquisition of Pharmatek-PMC

Established in 1984 in	Furtherly developed in
Brembate (Bergamo) as an	the Cosmetic and
R&D laboratory that applied	Biocide sectors thanks
Pharmaceutical	to the acquisition of
technologies to the new and	Pharmatek PMC occurred
fast growing Nutraceutical	in January 2021
industry

Developed soon into a CDMO in the Nutraceutical sector and immediately after in the Pharmaceutical

➝